iBio Announces Advancement of COVID-19 Vaccine Program
March 26 2020 - 7:30AM
iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a
biologics contract manufacturing organization and biotechnology
company, today announced that immunization studies for its
SARS-CoV-2 Virus-Like Particle (“VLP”) program (“IBIO-200”) are
proceeding at Texas A&M University System (“TAMUS”)
laboratories. The work is being performed as part of the Master
Joint Development Agreement established between iBio and TAMUS in
2016.
“This next stage of work on IBIO-200 is
critically important as we seek to quickly enter the clinic with
one of our VLP candidates,” said Tom Isett, Co-Chairman & Chief
Executive Officer of iBio. “As we optimize our choice of adjuvants
with both VLP types we have developed, we are fortunate to have a
strong relationship with TAMUS that allows us to rapidly bring
their deep insight into the pathogenesis of coronaviruses and
experience with vaccine development to the task.”
iBio created its proprietary VLP candidates in
just a few weeks using its FastPharming System™.
iBio’s researchers then deployed this plant-based expression
platform’s rapid production capabilities to deliver VLPs suitable
for further development just weeks after the biologics were
designed.
“We see strong potential for the IBIO-200
program given that we have both the glycosylated and
non-glycosylated iBio VLPs as options for development,” said Dr.
James Samuel, Head of the Department of Microbial Pathogenesis and
Immunology at Texas A&M University. “We look forward to
completing the preclinical immunization studies for iBio to
determine the optimal combination of VLP and adjuvant to advance to
human clinical trials.”
About iBio, Inc.
iBio is a global leader in plant-based biologics
manufacturing. Its FastPharming System™ combines
vertical farming, automated hydroponics, and glycan engineering
technologies to rapidly deliver gram quantities of high-quality
monoclonal antibodies, vaccines, bioinks and other proteins. The
Company’s subsidiary, iBio CDMO LLC, provides
FastPharming Contract Development and
Manufacturing Services via its 130,000 square foot facility in
Bryan, Texas. Originally built in 2010 with funding from the U.S.
Defense Advanced Research Projects Agency (DARPA), iBio’s
FastPharming Facility was part of the “Blue Angel”
initiative to establish factories capable of rapid delivery of
medical countermeasures in response to a disease pandemic. iBio’s
FastGlycaneering Development Service™ includes an
array of new glycosylation technologies for engineering
high-performance recombinant proteins. Additionally, iBio is
developing proprietary products which include IBIO-100 for the
treatment of fibrotic diseases and IBIO-200, a COVID-19 vaccine.
For more information, visit www.ibioinc.com.
About The Texas A&M University
System
TAMUS is one of the largest systems of higher
education in the nation with a budget of $6.3 billion. The System
is a statewide network of 11 universities; a comprehensive health
science center; eight state agencies, including the Texas Division
of Emergency Management; and the RELLIS Campus. The Texas A&M
System educates more than 151,000 students and makes more than 22
million additional educational contacts through service and
outreach programs each year. System-wide, research and development
expenditures exceeded $1 billion in FY 2019 and helped drive the
state’s economy.
FORWARD-LOOKING
STATEMENTSSTATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED
TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS
COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND
THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY
ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND
DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS
THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN
THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
Contacts:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580 skilmer@ibioinc.com
Laylan CopelinThe Texas A&M University
System Vice Chancellor of Marketing and Communications (979)
458-6425 lcopelin@tamus.edu
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024